At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
MydCombicombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open Label, Phase 4 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution (Mydcombi®) Administered With the Mydcombi Dispenser for Pupil Dilation (THE MIST-2.1 STUDY)
In Brief
A Phase 4 clinical trial evaluating MydCombi for Mydriasis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Subjects will receive ½ of the approved dose of MydCombi to determine the dilation curve with the reduced dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMydriasis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
Enrollment StartNov 2023
Primary CompletionJan 2024
First PostedJan 2024
TodayJul 2026
First PostedJan 22, 2024
Enrollment StartNov 28, 2023
Primary CompletionJan 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.4 years ago
Interventions
MydCombicombination
A single metered spray administered with the MydCombi dispenser